AXON vs. CORT
AXON (Axon Enterprise, Inc.) and CORT (Corcept Therapeutics Incorporated) are both stocks. AXON operates in Aerospace & Defense (Industrials), while CORT operates in Biotechnology (Healthcare). Over the past 10 years, AXON returned 33.16%/yr vs 32.26%/yr for CORT. At a 0.17 correlation, their price movements are largely independent.
Performance
AXON vs. CORT - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, AXON achieves a -11.55% return, which is significantly lower than CORT's 174.02% return. Both investments have delivered pretty close results over the past 10 years, with AXON having a 33.16% annualized return and CORT not far behind at 32.26%.
AXON
- 1D
- 2.12%
- 1M
- 9.99%
- 6M
- -18.07%
- YTD
- -11.55%
- 1Y
- -29.17%
- 3Y*
- 40.78%
- 5Y*
- 22.38%
- 10Y*
- 33.16%
- ALL TIME*
- 30.86%
CORT
- 1D
- -1.34%
- 1M
- 16.92%
- 6M
- 116.83%
- YTD
- 174.02%
- 1Y
- 41.09%
- 3Y*
- 57.58%
- 5Y*
- 36.28%
- 10Y*
- 32.26%
- ALL TIME*
- 9.65%
Liquidity Comparison
| Position | Avg. Volume Value (2W) | Avg. Volume Value (1M) | Avg. Volume Value (3M) |
|---|---|---|---|
| $355.64M | $556.75M | $522.77M | |
| $110.38M | $103.07M | $82.67M |
AXON vs. CORT - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
AXON Axon Enterprise, Inc. | -11.55% | -4.44% | 130.06% | 55.69% | 5.69% | 28.13% | 67.21% | 67.50% | 65.09% | 9.32% |
CORT Corcept Therapeutics Incorporated | 174.02% | -30.94% | 55.14% | 59.92% | 2.58% | -24.31% | 116.20% | -9.43% | -26.02% | 148.76% |
Correlation
The correlation between AXON and CORT is 0.11, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.11 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.17 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.23 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.20 |
Correlation (All Time) Calculated using the full available price history since Apr 14, 2004 | 0.17 |
The correlation between AXON and CORT shifts across timeframes, from 0.11 (1 year) to 0.23 (5 years), reflecting how their relationship changes across market environments.
Fundamentals
AXON:
$40.49B
CORT:
$10.24B
AXON:
$2.37
CORT:
$0.42
AXON:
211.82
CORT:
229.57
AXON:
0.06
CORT:
114.36
AXON:
14.64
CORT:
14.21
AXON:
11.72
CORT:
15.61
AXON:
$2.98B
CORT:
$769.10M
AXON:
$1.77B
CORT:
$755.64M
AXON:
$156.24M
CORT:
$3.66M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
AXON vs. CORT — Risk / Return Rank
AXON
CORT
AXON vs. CORT - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Axon Enterprise, Inc. (AXON) and Corcept Therapeutics Incorporated (CORT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| AXON | CORT | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.03 | ||
| Sortino ratioReturn per unit of downside risk | -1.58 | ||
| Omega ratioGain probability vs. loss probability | 0.95 | 1.24 | -0.30 |
| Calmar ratioReturn relative to maximum drawdown | -0.49 | 0.64 | -1.13 |
| Martin ratioReturn relative to average drawdown | -0.77 | 1.17 | -1.94 |
Loading charts...
Drawdowns
AXON vs. CORT - Drawdown Comparison
The maximum AXON drawdown since its inception was -91.78%, roughly equal to the maximum CORT drawdown of -94.29%. Use the drawdown chart below to compare losses from any high point for AXON and CORT.
Loading charts...
Drawdown Indicators
| AXON | CORT | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -91.78% | -94.29% | +2.51% |
Max Drawdown (1Y)Largest decline over 1 year | -60.28% | -64.40% | +4.12% |
Max Drawdown (3Y)Largest decline over 3 years | -60.28% | -71.85% | +11.57% |
Max Drawdown (5Y)Largest decline over 5 years | -60.28% | -71.85% | +11.57% |
Max Drawdown (10Y)Largest decline over 10 years | -60.28% | -71.85% | +11.57% |
Current DrawdownCurrent decline from peak | -42.32% | -16.51% | -25.81% |
Average DrawdownAverage peak-to-trough decline | -43.59% | -53.29% | +9.70% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 37.84% | 35.23% | +2.61% |
Volatility
AXON vs. CORT - Volatility Comparison
Axon Enterprise, Inc. (AXON) has a higher volatility of 20.65% compared to Corcept Therapeutics Incorporated (CORT) at 14.26%. This indicates that AXON's price experiences larger fluctuations and is considered to be riskier than CORT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| AXON | CORT | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 20.65% | 14.26% | +6.39% |
Volatility (6M)Calculated over the trailing 6-month period | 47.97% | 42.59% | +5.38% |
Volatility (1Y)Calculated over the trailing 1-year period | 58.54% | 77.23% | -18.69% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 48.86% | 74.75% | -25.89% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 49.58% | 67.26% | -17.68% |
Dividends
AXON vs. CORT - Dividend Comparison
Neither AXON nor CORT has paid dividends to shareholders.
Financials
AXON vs. CORT - Financials Comparison
This section allows you to compare key financial metrics between Axon Enterprise, Inc. and Corcept Therapeutics Incorporated. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
AXON vs. CORT - Profitability Comparison
AXON - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jul 2026, Axon Enterprise, Inc. reported a gross profit of 477.29M and revenue of 807.35M. Therefore, the gross margin over that period was 59.1%.
CORT - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jul 2026, Corcept Therapeutics Incorporated reported a gross profit of 162.02M and revenue of 164.90M. Therefore, the gross margin over that period was 98.3%.
AXON - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jul 2026, Axon Enterprise, Inc. reported an operating income of 29.24M and revenue of 807.35M, resulting in an operating margin of 3.6%.
CORT - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jul 2026, Corcept Therapeutics Incorporated reported an operating income of -49.60M and revenue of 164.90M, resulting in an operating margin of -30.1%.
AXON - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jul 2026, Axon Enterprise, Inc. reported a net income of 169.31M and revenue of 807.35M, resulting in a net margin of 21.0%.
CORT - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jul 2026, Corcept Therapeutics Incorporated reported a net income of -31.20M and revenue of 164.90M, resulting in a net margin of -18.9%.
Frequently Asked Questions
AXON and CORT have a correlation of 0.11, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
AXON has higher volatility (20.65%) compared to CORT (14.26%). In terms of maximum drawdown, AXON dropped -91.78% vs CORT's -94.29%.
CORT currently has the higher Sharpe Ratio (0.53 vs -0.50), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for AXON and CORT
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer